Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene
- 1 January 1997
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 112 (2) , 181-189
- https://doi.org/10.1016/s0304-3835(96)04581-8
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- University of Tokushima
This publication has 22 references indexed in Scilit:
- Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminusCell, 1995
- Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude miceCancer Letters, 1995
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNANature, 1994
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- p53 Mutations in Human CancersScience, 1991
- Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 1991
- Biological effects and binding properties of transforming growth factor-β on human oral squamous cell carcinoma cellsExperimental Cell Research, 1990
- A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failureCardiovascular Drugs and Therapy, 1990
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970